Sign In
Buy CUE
$26.84
-3.56 (-11.71%)
At Close: Jul 31, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
04:20pm, Monday, 31'st Mar 2025
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 29'th Nov 2024
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
08:00am, Monday, 25'th Nov 2024
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
06:25pm, Thursday, 14'th Nov 2024
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.24 per share a year ago.
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
04:05pm, Thursday, 14'th Nov 2024
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma Announces Strategic Organizational Transition
08:00am, Thursday, 14'th Nov 2024
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
11:26pm, Thursday, 26'th Sep 2024
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma Announces Proposed Public Offering
11:10pm, Thursday, 26'th Sep 2024
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma Announces Proposed Public Offering
04:27pm, Thursday, 26'th Sep 2024
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and m
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
08:00am, Monday, 09'th Sep 2024
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript
08:17pm, Monday, 19'th Aug 2024
Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2024 Earnings Conference Call August 19, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Anish Suri - President & Chief Scientific Officer Matteo Leviset
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
04:05pm, Monday, 19'th Aug 2024
BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
08:45pm, Wednesday, 14'th Aug 2024
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago.
